Rocket Pharmaceuticals (NASDAQ:RCKT) reported that it has voluntarily withdrawn its biologics marketing application to the U.S. FDA for mozafancogene autotemcel or RP-L102, an investigational gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results